{"result": "(\"entity\"<|>EPA<|>ORGANIZATION<|>EPA is a treatment administered to patients undergoing hematopoietic cell transplantation to reduce inflammation and complications such as EICH.)\n##\n(\"entity\"<|>EICH<|>EVENT<|>EICH refers to the acute and chronic graft-versus-host disease that can occur after hematopoietic cell transplantation.)\n##\n(\"entity\"<|>BONE MARROW TRANSPLANTATION<|>EVENT<|>Bone marrow transplantation is a medical procedure involving high doses of chemotherapy followed by the infusion of hematopoietic cells to treat various conditions.)\n##\n(\"entity\"<|>NUTRITIONAL SUPPORT<|>ORGANIZATION<|>Nutritional support is critical for patients post-transplant to manage complications and maintain health.)\n##\n(\"entity\"<|>QUIMIOTERAPIA<|>EVENT<|>Quimioterapia is a treatment involving the use of drugs to kill cancer cells, often used before bone marrow transplantation.)\n##\n(\"relationship\"<|>EPA<|>EICH<|>EPA is used to reduce the incidence and severity of EICH in patients undergoing transplantation<|>8)\n##\n(\"relationship\"<|>BONE MARROW TRANSPLANTATION<|>EICH<|>Bone marrow transplantation can lead to EICH as a complication<|>7)\n##\n(\"relationship\"<|>BONE MARROW TRANSPLANTATION<|>NUTRITIONAL SUPPORT<|>Nutritional support is essential for patients undergoing bone marrow transplantation to prevent malnutrition<|>6)\n##\n(\"relationship\"<|>QUIMIOTERAPIA<|>BONE MARROW TRANSPLANTATION<|>Quimioterapia is administered prior to bone marrow transplantation to prepare the patient<|>9)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: | Adultos | Tumores hematológicos y sólidos | No claro | Ingesta oral de > 50% de requerimientos | 0,97 g/kg por día |\n| Schloerb95 | Oral | Auto y Alo | Adultos | Tumores hematológicos y sólidos | No claro | No claro | 10 g 3 x por día |\n| Sykorova96 | i.v. | Auto | Adultos | Tumores hematológicos | Comienzo del acondicionamiento | Leucocitos > 1,0 x 109/l o ingesta oral suficiente | 0,5 g/kg por día |\n| Ziegler59, 97-100 | i.v. | Alo | Adultos | Tumores hematológicos | D + 1 | Ingesta oral de > 50% de requerimientos | 0,285 g/kg por día |\n\nadministran 600 mg/3 veces/día de EPA desde el día 21 pretrasplante hasta el día 180 postrasplante, detectándose una disminución significativa del TNF-α, INF-α, leucotrieno B4, IL-10, tromboxano A2 y PGI2 en el grupo tratado con EPA. En ambos trabajos se objetivó una disminución tanto de la incidencia76 como de la severidad77 de la EICH. El EPA puede disminuir la EICH, suprimiendo los dos principales mecanismos implicados en la respuesta inflamatoria sistémica (RIS): aumento de las citokinas inflamatorias y disfunción progresiva del endotelio vascular78. A pesar del resultado de estos estudios, siguen existiendo consideraciones teóricas sobre la seguridad de modificar el sistema inmunológico en pacientes con riesgo de desarrollar EICH75. Por este motivo se precisan ensayos clínicos adecuadamente diseñados en los que se estudie este punto antes de poder recomendar nutrientes inmunomoduladores.\n\n## 9. Resumen\n\nEl trasplante de células hematopoyéticas consiste en la administración de altas dosis de quimioterapia, con o sin irradiación corporal, seguida de infusión intravenosa de células hematopoyéticas. Se emplea en el tratamiento de diversas patologías, tanto congénitas como adquiridas, y dentro de estas, tumorales y no tumorales.\n\nEn general, el estado nutricional de los candidatos es bueno, incluso en los tumores de origen hematológico. Una excepción la constituyen los enfermos con neoplasias sólidas que suelen estar previamente desnutridos. En el período postrasplante el riesgo de desnutrición aumenta como consecuencia de complicaciones como la anorexia, las náuseas y los vómitos secundarios a los efectos adversos de los fármacos quimioterápicos y de los corticoides; la mucositis secundaria a las altas dosis de quimioterapia y a la irradiación corporal total; la EICH tanto aguda como crónica; la enfermedad venoclusiva hepática y diversas alteraciones metabólicas. La necesidad de soporte nutricional artificial es mayor en el trasplante alogénico que en el trasplante autólogo, debido a los mayores requerimientos calórico-proteicos, a la mayor incidencia de EICH y a la mayor severidad de la mucositis.\n\nLa dieta oral debe ser la opción inicial. Hay que tener en cuenta que la bandeja, la vajilla, los cubiertos utilizados y los alimentos son portadores de microorganismos. Aunque hasta la fecha no se ha demostrado que deban ser estériles, en la práctica clínica se debe procurar disminuir al mínimo posible el porcentaje de microorganismos que presentan. Cuando el paciente no puede cubrir sus requerimientos nutricionales mediante alimentación oral, es preciso plantearse el tratamiento con nutrición artificial. La NE es más fisiológica y generalmente más barata que la NP. Además, se asocia a menor frecuencia de colestasis, me-\n---\n670     BLOQUE: NUTRICIÓN EN ONCOLOGÍA\n\nnor duración de la diarrea y menor incidencia de hemocultivos positivos que la NP. A pesar de esto, tiene una serie de complicaciones relacionadas tanto con la forma de administración como con la tolerancia a la fórmula enteral. Si no es factible la nutrición por vía enteral, sería preciso recurrir a la NP. Esta última es una terapia nutricional segura pero no exenta de complicaciones, siendo las más frecuentes en este tipo de enfermos la infección de la vía venosa central y la hiperglucemia.\n\nEn el momento actual no se recomienda el uso de glutamina ni de fórmulas inmunomoduladoras en el soporte nutricional de estos pacientes, en espera de ensayos clínicos de mayor tamaño y adecuado diseño que despejen las controversias existentes.\n\n## 10. Bibliografía\n\n1. Bociek RG, Stewart DA, Armitage JO. Bone marrow transplantation-current-concepts. J Invest Med 1995; 43:127-35.\n2\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}